Processing

Please wait...

Settings

Settings

Goto Application

1. IN201647009984 - 1 2 4 OXADIAZOLE DERIVATIVES AS IMMUNOMODULATORS

Office
India
Application Number 201647009984
Application Date 22.03.2016
Publication Number 201647009984
Publication Date 31.08.2016
Grant Number 317056
Grant Date 30.07.2019
Publication Kind B
IPC
C07D 271/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
C07D 285/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
285Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/-C07D283/183
01Five-membered rings
02Thiadiazoles; Hydrogenated thiadiazoles
04not condensed with other rings
081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
A61K 31/424
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
424condensed with heterocyclic ring systems, e.g. clavulanic acid
Applicants AURIGENE DISCOVERY TECHNOLOGIES LIMITED
Inventors SASIKUMAR Pottayil Govindan Nair
RAMACHANDRA Muralidhara
NAREMADDEPALLI Seetharamaiah Setty Sudarshan
Priority Data 4011/CHE/2013 06.09.2013 IN
Title
(EN) 1 2 4 OXADIAZOLE DERIVATIVES AS IMMUNOMODULATORS
Abstract
(EN) The present invention relates to 1 2 4 oxadiazole and 1 2 4 thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and 5 derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD 1 PD L1 or PD L2 and therapies using them.